GLP-1s take bite out of stomach weight-loss surgeries: Research
A new study published in JAMA Surgery examined trends in the use of metabolic and bariatric surgery in the U.S. between 2022 and 2024. As use of GLP-1 drugs increased by 140.4 percent during that period, bariatric surgery rates fell by 34 percent, researchers found after analyzing data from 11.7 million patients diagnosed with obesity or diabetes. The findings align with a separate recent study from Loyola University Chicago, which found the number of metabolic and bariatric surgeries in the U.S. dropped below 200,000 in 2024 for the first time since 2020.
- ▪A new study published in JAMA Surgery examined trends in the use of metabolic and bariatric surgery in the U.S. between 2022 and 2024.
- ▪As use of GLP-1 drugs increased by 140.4 percent during that period, bariatric surgery rates fell by 34 percent, researchers found after analyzing data from 11.7 million patients diagnosed with obesity or diabetes.
- ▪The findings align with a separate recent study from Loyola University Chicago, which found the number of metabolic and bariatric surgeries in the U.S. dropped below 200,000 in 2024 for the first time since 2020.
The Hill files mainly under politics. We currently carry 1,451 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | The Hill |
| Canonical URL | https://thehill.com/policy/healthcare/5893017-glp-1-weight-loss-surgery-comparison-study/ |
| Publication time | Mon, 25 May 2026 15:38:39 +0000 |
| Retrieval time | 2026-05-25T15:52:38.240Z |
| Last seen | 2026-05-25T15:52:39.262Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | rzrt447fTsnq |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
Healthcare GLP-1s take bite out of stomach weight-loss surgeries: Research Comments: by Michael Ramsey - 05/25/26 11:38 AM ET Comments: Link copied by Michael Ramsey - 05/25/26 11:38 AM ET Comments: Link copied NOW PLAYING (NewsNation) — Increased use of GLP-1 drugs to treat obesity appears to be significantly reducing the number of surgeries that were once the primary option for dramatic weight loss. A new study published in JAMA Surgery examined trends in the use of metabolic and bariatric surgery in the U.S. between 2022 and 2024. As use of GLP-1 drugs increased by 140.4 percent during that period, bariatric surgery rates fell by 34 percent, researchers found after analyzing data from 11.7 million patients diagnosed with obesity or diabetes.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at The Hill.